Rfk Jr. Ally Says New Glyphosate Study 'backs Epa Into A Corner'
A scientific paper requested by Health Secretary Robert F. Kennedy Jr. and his former adviser Calley Means takes another shot at one of the Make America Healthy Again movement’s biggest goals.
The paper posted on a public research repository Friday lays out the existing scientific research linking glyphosate, the main ingredient in the weedkiller Roundup, with cancer. The paper has not yet gone through the standard scientific review process, including peer review and publication in a scientific journal.
Its timing is aimed at forcing the Trump administration to more stringently regulate the chemical, a top target of MAHA activists. EPA, which oversees pesticide approvals, is in the process of reviewing health research on glyphosate and Monday is the deadline for scientific studies to be considered.
The study "really backs EPA into a corner," Means argued in an interview. Means resigned from HHS last month citing frustration with the lack of progress on MAHA’s priorities.
The move stands to reignite the brawl within the Trump administration over an issue that pits Kennedy and MAHA activists against the president’s traditional farm and business allies.
The paper comes amid a major realignment of power within the White House, after chief of staff Susie Wiles departed following Republicans’ midterm losses and Stephen Miller, a MAHA ally, took over her role.
EPA spokesperson Cora Mandy said the agency "is aware” of the HHS review and “will evaluate it the same way we evaluate every study." She pushed back against Means' characterization that the study will force EPA’s hand.
"We want as much high-quality research in the record as possible,” Mandy said. “Every relevant, quality study gets a seat at the table, and this one is no exception. We're working hand in hand with our HHS colleagues."
The White House referred questions to HHS.
HHS spokesperson Emily Hilliard said the reviews have been presented to an EPA-HHS work group and acknowledged "EPA retains responsibility for regulatory decisions."
EPA’s last review of glyphosate, from 2020, concluded that the herbicide is not likely to cause cancer in humans, but a federal appeals court threw out that review two years later, ruling that the agency didn’t do enough to consider the chemical’s cancer risks. The International Agency for Research on Cancer, a division of the World Health Organization, classified glyphosate as "probably carcinogenic to humans" in 2015.
EPA has repeatedly pushed back the timeline for the updated assessment, which Mandy said the agency now expects to release in "early 2027."
The outcome of EPA’s new review will have major implications for Roundup manufacturer Bayer and other pesticide companies. If the agency concludes glyphosate is linked to cancer, they would have to disclose that on the product label — a requirement that could fuel class action lawsuits against manufacturers from individuals who claim they were sickened by their products.
So far, President Donald Trump has gone out of his way to protect the weedkiller, The Trump administration backed Bayer in a Supreme Court case this summer over whether states could require more stringent product labeling. and the president signed an executive order in February extending national security protections to glyphosate — moves that outraged MAHA activists.
Kennedy, a former environmental attorney who worked on class action lawsuits over glyphosate, earlier this year said he was pouring "huge amounts of money" into researching the chemical in hopes of influencing the EPA review of glyphosate.
In September, as the midterm elections loomed, Kennedy and EPA Administrator Lee Zeldin formally committed to working together on the glyphosate review.
The paper released Friday is not new research on the health effects of the chemical, but rather an analysis of the body of existing research using a set of scientific rules to draw overarching conclusions. It was conducted by scientists at the National Institute of Environmental Health Sciences and National Toxicology Program, two subagencies of HHS, and scientists with Integrated Laboratory Systems, a federal contractor.
In an interview, Means said he deliberately kept the scientific project secret from the Trump administration officials who oversee chemical regulations at EPA. One of those officials, Nancy Beck, formerly served as a top chemical industry expert and has become a target of MAHA activists.
"This has been part of a two-year strategy to conduct these studies without Nancy Beck knowing,” Means said. “There will be unrelenting political and legal pressure on Nancy Beck if she doesn’t take this into account.”
Beck, principal deputy assistant administrator in EPA's chemicals office, previously directed regulatory science policy for the American Chemistry Council, a trade group representing the biggest chemical and pesticide manufacturers.
Beck referred questions to EPA's press office.
"If it's relevant and of sufficient quality, we'll address it in the registration review record and explain how it informs our conclusions," Mandy said.
There's no guarantee EPA will adopt the findings from the HHS analysis, and environmental groups have long accused regulators of cherry picking which studies it takes into consideration when making registration decisions.
MAHA activists have accused Zeldin of making regulatory decisions that are overly aligned with industry, culminating in a petition last year calling for Trump to fire him. As Zeldin sought to assuage those concerns, he vowed to rely on what he describes as "gold standard science."
Prominent activists now say the HHS glyphosate study will test that commitment.
“I think it's very clear that EPA is now in a position where, if it doesn't classify glyphosate as likely to be carcinogenic to humans, then it is not following EPA's own guidelines for carcinogen risk assessment or gold standard science,” said Alexandra Muñoz, an independent toxicologist who has worked with MAHA advocates.
Meghan McCormick, a spokesperson for Ruveon, a legal entity launched by Bayer to manage U.S. glyphosate business, dismissed the review as an unpublished manuscript awaiting peer review, “so its methodology, interpretation, and conclusions should be considered preliminary.”